Nephrogen, a biotech startup founded by Stanford graduate Demetri Maxim, is developing an AI‑driven delivery system for gene‑editing medicines aimed at treating polycystic kidney disease (PKD). After a personal battle with PKD, Maxim combined insights from a 2021 Nature study with advanced screening to create a vehicle that is claimed to be 100 times more efficient than existing FDA‑approved options. The company, a finalist in TechCrunch Disrupt’s Startup Battlefield, is seeking a $4 million seed round to move its delivery platform and a companion drug into clinical trials, potentially as early as 2027. Read more →